Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phosphorylation of serines 287/288 in DEK regulates cell-type-specific chromatin occupancy and compaction [ChIP-Seq]

ABSTRACT: The conserved multifunctional chromatin modulator and oncogene DEK exhibits context-dependent genomic binding and function, but how these activities are regulated in cancer remains poorly understood. Using multi-omics and biochemical approaches, we find that while DEK predominantly occupies promoter-proximal regions in HeLa cells and primary melanocytes, its chromatin binding is dramatically reduced in melanoma cell lines—despite DEK overexpression. We attributed this to CK2-mediated phosphorylation, which governs DEK chromatin association and transcriptional output in a cell-type-specific manner. Phosphoproteomics identified 34 phosphorylation sites, including S287 and S288 within the DEK C-terminal DNA-binding domain. Strikingly, CK2 inhibition and concomitant loss of phosphorylation at S287/S288 triggered DEK redistribution to promoter regions, coinciding with transcriptional repression of oncogenic pathways and global chromatin compaction. Melanoma subtypes showed divergent responses: NRAS-mutant cells displayed dynamic, phosphorylation-dependent DEK redistribution, whereas BRAF-mutant cells lacked detectable DEK binding. Our work establishes DEK as a phosphorylation-sensitive regulator of chromatin states, with CK2-mediated modification orchestrating its tumor-specific regulatory functions. These findings nominate phospho-DEK as a potential biomarker and therapeutic target in melanoma and possibly other cancers.

ORGANISM(S): Homo sapiens

PROVIDER: GSE324916 | GEO | 2026/03/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CK2-mediated DEK Phosphorylation Drives PBX3 Overexpression: A Core Event in Hematopoietic Stem Cell-to-Leukemia Stem Cell Transformation [CUT&Tag]

Project description:Leukemia stem cells (LSCs) possess self-renewal capacity and are largely refractory to conventional chemotherapy, thereby driving relapse and treatment failure in acute myeloid leukemia (AML). Here, we identify DEK as a crucial oncogenic factor aberrantly overexpressed in relapsed AML, with markedly increased phosphorylation by casein kinase 2 (CK2), correlating with poor patient prognosis. Using human AML cells and mouse models, we demonstrate that loss of DEK or phospho-mutants DEK, specifically at Ser306/Ser308/Ser311/Ser312 induces AML cells proliferation, differentiation, and weakened LSCs stemness. Mechanistically, phosphorylated DEK recruits GABPA to activate PBX3 transcription, thereby driving a leukemic transcriptional program. Importantly, targeting DEK or pharmacologic inhibition of CK2 using the specific inhibitor CX-4945 disrupts DEK phosphorylation and markedly sensitizes AML cells to venetoclax treatment, providing a rationale for a potential combination therapeutic strategy. Collectively, our findings uncover a unique and critical role of phosphorylated DEK as a transcriptional coactivator in AML and highlight the CK2-DEK/GABPA-PBX3 axis as a promising therapeutic target for AML.

2025-09-30 | GSE309284 | GEO

CK2-mediated DEK Phosphorylation Drives PBX3 Overexpression: A Core Event in Hematopoietic Stem Cell-to-Leukemia Stem Cell Transformation [ATAC-seq]

2025-09-30 | GSE309177 | GEO

CK2-mediated DEK Phosphorylation Drives PBX3 Overexpression: A Core Event in Hematopoietic Stem Cell-to-Leukemia Stem Cell Transformation [RNA-seq]

2025-09-30 | GSE309176 | GEO

Transcriptional Profiling of Lineage Depleted Dek-KO Murine Bone Marrow Treated with Exogenous DEK

Project description:Nuclear protein DEK is an endogenous DNA-binding chromatin factor regulating hematopoiesis. DEK is one of only two known secreted nuclear chromatin factors, but whether and how extracellular DEK regulates hematopoiesis is not known. We demonstrate that extracellular DEK greatly enhances ex vivo expansion of cytokine-stimulated human and mouse hematopoietic stem cells, and regulates hematopoiesis in vivo and in vitro. These effects are mediated through chemokine receptor CXCR2 and heparan sulfate proteoglycans, and are associated with enhanced phosphorylation of ERK1/2, AKT and p38 MAPK. Thus, DEK acts as a hematopoietic cytokine, with potential for clinical applicability.

2019-02-22 | GSE126875 | GEO

Structural basis of the DEK-nucleosome complex and its functional implications

Project description:The nuclear factor Dek is notably enriched within chromatin; nevertheless, the precise binding mechanism of Dek to the nucleosome remains elusive. In this study, we employ cryo-electron microscopy (cryo-EM) to elucidate the high-resolution structure of the Dek-Nucleosome Core Particle (NCP) complex. We identify specific domains responsible for DEK interaction with the histone octamer and DNA within the nucleosome. The veracity of these binding domains is confirmed through a series of meticulous biochemical experiments. Subsequently, cellular experiments reveal that Dek lacking nucleosome-binding capacity exhibits a deficiency in chromatin interaction. Remarkably, this impairment induces a shift towards the primitive endoderm fate in mouse embryonic stem cells, underscoring the pivotal role of Dek in determining cell fate through its nucleosomal interactions.

2023-12-31 | GSE247796 | GEO

Structural basis of the DEK-nucleosome complex and its functional implications (CUT&Tag)

2024-01-15 | GSE253062 | GEO

Structural basis of the DEK-nucleosome complex and its functional implications [CUT&Tag]

2025-01-01 | GSE281372 | GEO

Gene expression comparison in control and DEK oncogene depleted human melanoma cell lines

Project description:Gene expression SK-Mel-103 melanoma cell line to find genes controled by DEK oncogene

2017-12-21 | GSE83614 | GEO

Inhibition of DEK contributes to the tolerance of replication stress and restores HSC function in Fanconi anemia (9-ATAC)

Project description:Replication stress drives functional decline in HSCs and is a major driver of BM failure in Fanconi anemia (FA). At present, how HSCs respond and counteract replication stress remains largely unknown. Using integrated multi-omics, we demonstrate that global chromatin relaxation is a prerequisite for the activation of stress-responsive genes and replication fork stabilization/progression in HSCs under replication stress. The reduced DEK (a chromatin architectural protein) contributes to the chromatin relaxation in HSCs, whereas DEK-overexpressed HSCs are confronted with a strong replication challenge, resulting in impaired HSC maintenance and hematopoiesis. Fancd2 deletion induces DEK expression and causes replication stress in HSCs, while haploinsufficiency of DEK promotes chromatin opening in Fancd2-deficient HSCs and substantially recovers HSC function. Notably, DEK expression is abnormally up-regulated in bone marrow (BM) CD34+ cells from FA patients. Inhibition of DEK significantly restores the proliferation capacity in vitro and engraftment in vivo of BM CD34+ cells from FA patients. At the molecular level, we identify that the transcriptional factor ATF2 directly promotes DEK transcription, mainly relying on the phosphorylated ATF2 (Thr69/71). Wild-type HSCs reduces DEK expression to counteract replication stress through the ATR kinase to phosphorylate ATF2 at Ser490/498. However, Fancd2 deficiency induces hyper-phosphorylation of p38 that further phosphorylates ATF2 at Thr69/71, causing DEK accumulation in HSCs. Collectively, our findings provide the first evidence of a functional link between chromatin relaxation and replication stress tolerance in HSCs, and highlight DEK as a potential molecular target for FA.

2025-01-03 | GSE267488 | GEO

Inhibition of DEK contributes to the tolerance of replication stress and restores HSC function in Fanconi anemia [11-ATAC]

2025-01-03 | GSE281512 | GEO